Larotrectinib Alternatives Compared
| Larotrectinib | Keytruda (pembrolizumab) | Pembrolizumab |
|
|---|
| Larotrectinib | Keytruda (pembrolizumab) | Pembrolizumab |
|
|||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Solid Tumors. Larotrectinib may also be used for purposes not listed in this medication guide. |
Prescription only
Keytruda is an immunotherapy treatment called a checkpoint inhibitor that helps your immune system fight cancer and is used to treat many different types of cancer in adults and children including... View more |
Prescription only
Prescribed for Bladder Cancer, Cervical Cancer, Breast Cancer, Biliary Tract Tumor, Colorectal Cancer, Endometrial Cancer, Esophageal Carcinoma, Gastric Cancer, Head and Neck Cancer, Hepatocellular... View more |
Related suggestions Solid Tumors
|
|||||||
| More about Larotrectinib | More about Keytruda (pembrolizumab) | More about Pembrolizumab | ||||||||
| Ratings & Reviews | ||||||||||
|
Larotrectinib has an average rating of 9.0 out of 10 from a total of 1 ratings on Drugs.com. 100% of reviewers reported a positive effect, while 0% reported a negative effect. |
Keytruda has an average rating of 4.9 out of 10 from a total of 253 ratings on Drugs.com. 40% of reviewers reported a positive effect, while 48% reported a negative effect. |
Pembrolizumab has an average rating of 5.2 out of 10 from a total of 280 ratings on Drugs.com. 43% of reviewers reported a positive effect, while 45% reported a negative effect. |
||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||
|
View all Larotrectinib side effects |
View all Keytruda side effects |
View all Pembrolizumab side effects |
||||||||
| Drug Class | ||||||||||
| Generic Availability | ||||||||||
|
N/A |
N/A |
N/A |
||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||
|
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
View all Keytruda prices |
We could not find an exact match for this medicine. Try searching the Price Guide directly. |
||||||||
| Dosage Forms | ||||||||||
|
N/A |
|
N/A |
||||||||
| Brand Names | ||||||||||
| Vitrakvi |
N/A |
Keytruda | ||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||
|
2.9 hours |
624 hours |
624 hours |
||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||
| Pregnancy Category | ||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
||||||||
| Drug Interactions | ||||||||||
|
A total of 511 drugs are known to interact with Larotrectinib:
|
A total of 588 drugs are known to interact with Keytruda:
|
A total of 588 drugs are known to interact with Pembrolizumab:
|
||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||
| Disease Interactions | ||||||||||
| First Approval Date | ||||||||||
|
November 26, 2018 |
N/A |
N/A |
||||||||
| WADA Class View classifications | ||||||||||
|
N/A |
N/A |
N/A |
||||||||
| More Information | ||||||||||
| Patient Resources | ||||||||||
| Professional Resources | ||||||||||
| Related Treatment Guide | ||||||||||
|
|
|||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.